TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03169504
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks.
Study: NCT01874431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02367820
Drug: NKTR-181 BID tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 tablets 100-600 mg twice daily (BID)
Study: NCT03507465
Drug: Letrozole Plus Low-Dose Metronomic Capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Letrozole Plus Low-Dose Metronomic Capecitabine
Study: NCT03507465
Drug: EC-T
Normalized name: Spec-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/Cyclophosphamide Followed by Docetaxel
Study: NCT02072161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, taken once daily oral
Study: NCT02072161
Drug: Statin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Study: NCT00473083
Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
Study: NCT03186326
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Study: NCT01959100
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg x 3/week per os during a meal for a period of 2 years
Study: NCT01959100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg x 3/week during a meal for a period of 2 years
Study: NCT03789643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT00415740
Drug: ELC200 (carbidopa+levodopa+entacapone)
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02877979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01159574
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Study: NCT00286182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01787552
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787552
Drug: INC424
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00752570
Drug: AMG 386 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
Study: NCT00752570
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
Study: NCT00001416
Drug: CEREDASE™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02344303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00253903
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01458275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - one actuation per nostril
Study: NCT01233635
Drug: start cozaar
Approvals — FDA: no, EMA: no, PMDA: no
Description: start cozaar
Study: NCT01233635
Drug: continue cozaar
Approvals — FDA: no, EMA: no, PMDA: no
Description: continue cozaar
Study: NCT02419755
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
Study: NCT02419755
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
Study: NCT02419755
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO).
Study: NCT02419755
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT01474486
Drug: Micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
Study: NCT03839134
Drug: Lidocaine Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
Study: NCT02830139
Drug: Oxaliplatin , Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study: NCT05002361
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml of isotonic saline
Study: NCT00417066
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060411
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00060411
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04054830
Drug: Voltaren Ophtha 1 mg/ml, GSK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study: NCT04054830
Drug: Monopex 1 mg/ml, Théa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
Study: NCT00111761
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Study: NCT01515319
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical volume to that of Y242
Study: NCT02386852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
Study: NCT00619476
Drug: GEn 1200mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 1200mg/day
Study: NCT00619476
Drug: GEn 2400mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 2400mg/day
Study: NCT00619476
Drug: GEn 3600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin enacarbil 3600mg/day
Study: NCT00619476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01560468
Drug: ITX 5061
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
Study: NCT03806049
Drug: TSR042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as IV infusion every three weeks
Study: NCT02462083
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT03244592
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day
Study: NCT00640081
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00640081
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00640081
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03131583
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day3\~Day8 qd
Study: NCT04298021
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: * In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks
Study: NCT00495586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill to be taken every eight hours for 8 days
Study: NCT02429050
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
Study: NCT00171249
Drug: STI571 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI571 capsules and tablets
Study: NCT00171249
Drug: STI571 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI571 capsules and tablets
Study: NCT03821038
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV twice a week at the same volume for 3 weeks
Study: NCT02174757
Drug: Inersan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT02174757
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT02527343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volanesorsen-matching placebo administered SC injection.
Study: NCT00211185
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study: NCT00211185
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study: NCT02873091
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00712673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
Study: NCT01852162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT04062695
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing placebo
Study: NCT03936569
Drug: Marketed Toothpaste
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed stannous fluoride (0.454%) toothpaste
Study: NCT03936569
Drug: Marketed Cavity Protection Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study: NCT01268059
Drug: MEDI-575
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
Study: NCT01474512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02749708
Drug: IRX5183
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
Study: NCT01142999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
Study: NCT01468831
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of minocycline in a pink opaque capsule
Study: NCT00083564
Drug: STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
Normalized name: holmium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01232283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
Study: NCT00986414
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00986414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03826563
Drug: oral melatonin tablets (NatureMade brand)
Normalized name: melatonin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin tablets
Study: NCT03232177
Drug: Anagre Cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
Study: NCT00465530
Drug: Gentamycin
Normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal irrigation
Study: NCT01338324
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg single dose on day 1
Study: NCT01742611
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02022514
Drug: Conventional medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00975936
Drug: [14C]-GSK706769
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50µg \[14C\]-GSK706769 containing 250 nCi
Study: NCT01198912
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: during 56 days
Study: NCT01198912
Drug: doxycycline 100 mg
Normalized name: doxycycline 100 MG
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: during 56 days
Study: NCT04346316
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken once daily (QD)
Study: NCT00794664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL weekly subcutaneous injections for 26 weeks
Study: NCT03080831
Drug: Glucion 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
Study: NCT03219437
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsule
Study: NCT04872283
Drug: IV Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
Study: NCT04872283
Drug: Ketorolac Pill
Normalized name: ketorolac Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
Study: NCT04872283
Drug: 5/325mg Oxycodone-Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
Study: NCT04872283
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
Study: NCT02344823
Drug: Placebo intake once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2, d1-3
Study: NCT00175227
Drug: intravenous saline hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mls half-normal saline
Study: NCT01994668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous administration of 0.9% saline over 1 minute
Study: NCT03567681
Drug: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Normalized name: oxcarbazepine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Study: NCT03383185
Drug: Progestin-only pills
Normalized name: Prostin E2 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of progestin-only pills during the follow-up period
Study: NCT01798251
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 850mg/m2 bid, d1-14, every 3 weeks
Study: NCT00124332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04509115
Drug: Short-acting opioid prescription for acute pain
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
Study: NCT02534038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00264927
Drug: SR121463B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00402597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet twice daily for 6 months.
Study: NCT01831856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, one capsule each evening with dinner.
Study: NCT02886728
Drug: Placebo to match MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule(s) administered orally once weekly
Study: NCT01602562
Drug: VACV tablets (Adults or pediatrics) or granules (pediatrics)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
Study: NCT03933488
Drug: TAK-994 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-994 placebo-matching tablets.
Study: NCT03071601
Drug: Lidocaine 1% Epinephrine 0.005mg/mL solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
Study: NCT04494373
Drug: Xgeva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Study: NCT00865475
Drug: Switching to LPV/r monotherapy (Kaletra)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
Study: NCT02481947
Drug: BLI400 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 gm BLI400 powder
Study: NCT00757341
Drug: SKI-606
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02949310
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468415
Drug: phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
Study: NCT02171416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03836664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is normal saline solution that will be supplied in container matched to Timolol container.
Study: NCT03186131
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the efficacy of oral Ibandronate in osteoporosis
Study: NCT03186131
Drug: Oral Ibandronate and Vitamin D
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
Study: NCT02357459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mL IA injection
Study: NCT02357459
Drug: TCA IR 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 mL IA injection